Introduction
Doxorubicin is one of the most effective chemotherapeutic agents, and is indicated for many cancers including breast cancers, lung cancers, and ovary cancers. However, the optimal clinical use of this agent is limited by its major adverse effect of cardiomyopathy which leads to congestive heart failure, which would cause a mortality of approximately 50% (1, 2) . Extensive research has suggested several possible mechanisms for its cardiomyopathy including apoptosis, oxidative stress, inactivated cardiomyocyte specific genes, and altered molecular signaling (for example, MAPKs) (3). However, unfortunately, no effective treatment for established doxorubicin cardiomyopathy is available. Therefore, there is a great need to identify novel targets to protect the heart from doxorubicin damage.
Recent developments in proteomic technology provide an opportunity for the discovery of novel molecular pathways and biomarkers of drug-induced toxicity. Especially, in a recent proteomic study using the common two-dimensional electrophoresis and mass spectrometry technologies, Kumar et al. (4) identified several oxidative stress response-related proteins differently regulated in rat cardiomyocytes and heart tissues exposed to doxorubicin. Compared with the traditional proteomic methods such as 2-DE
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Materials and Methods
Cell culture and treatment
C a r d i o m y o c y t e c e l l l i n e H 9 c 2 d e r i v e d f r o m embryonic rat heart by selective serial passages was obtained from the Cell Bank of Chinese Academy of Sciences (Shanghai, China) with the original source as American Type Culture Collection (ATCC) (Manassas, VA, USA). H9c2 cells were maintained in Dulbecco's modified Eagle's medium (DMEM, Gibco, Carlsbad, CA, USA) with 10% fetal calf serum (Gibco) at 37°C with 5% CO 2 . H9c2 cells were treated with doxorubicin (Sigma-Aldrich, St. Louis, MO, USA) at a clinically relevant concentration of 0.5 μM as described previously (6).
Flow cytometric analysis of 0.5 μM of doxorubicin on apoptosis of H9c2 cells
H9c2 cells without or with doxorubicin treatment at different time courses were collected and washed in PBS. After washing and staining with annexin V-FITC/ propidium iodide (PI), the apoptosis rate of H9c2 cells were detected using flow cytometry as directed by an Annexin V-FITC/PI Kit (Nanjing Kaiji Biological Inc., Nanjing, China).
Protein digestion and labeling with iTRAQ reagents
Protein extraction at 48 h was performed as described previously (7). Briefly, H9c2 cells treated with and without doxorubicin for 48 h were dissolved in lysis buffer (7 M urea, 2 M thiourea, 65 mM DTT, 0.1 mM PMSF) and protein concentrations were determined using the 2D Quant Kit (GE Healthcare, Uppsala, Sweden). Protein trypsin digestion and iTRAQ labeling were performed in accordance with the manuscript's protocol (Applied Biosystems, Carlsbad, CA, USA). After reduction and alkylation, 100 μg protein of each sample were digested with trypsin and labeled with iTRAQ reagents as follows: H9c2 cells treated with doxorubicin, iTRAQ reagent 113; and H9c2 cells treated without doxorubicin, iTRAQ reagent 115. The labeled digests were then combined for peptide separation.
Trypsin peptides fraction and mass spectrometry
The mixed peptides were fractionated using strong cation exchange (SCX) chromatography into 10 fractions. The peptides in these fractions were further separated using a C18 column on a Tempo LC nanoflow system, and spotted on stainless steel target plates using a MALDI spotting system (Applied Biosystems). Mass spectrometer 4800 MALDI TOF/ TOF Analyzer (Applied Biosystems) was used to perform tandem mass spectrometry acquisition in the positive ion mode. Only the most intense ion signals with S/N above 40 and excluding common trypsin autolysis peaks were selected as precursors for MS/ MS acquisition. The MS/MS data were searched using the MASCOT Database search engine (Matrix Science, London, UK) embedded into GPS-Explorer Software (Applied Biosystems) against the Swiss-Prot database with the following search parameters: peptide tol: 0.3 Da, MSMS tol: 0.6 Da, variable modification: oxidation (M), fixed modification: carboxymethyl (C). Proteins were identified with at least a 95% confidence level, and relative quantification of proteins was based on the ratio of peak areas of m/z 113 and 115 from the MS/MS spectra.
Gene ontology (GO) analysis
GO analysis was performed with the GSEABase package from the R statistical platform (http://www. r-project.org).
Western-blot
The iTRAQ analysis has been performed only once in this study, to confirm the expression variation of cathepsin B in H9c2 cells during doxorubicin treatment, and we further performed a Westernblot experiment in another independent series of samples, which is not the same as those used in the proteomic study. Whole cell extracts and nuclear protein extracts were prepared using a protein extraction kit (Beyotime Bio-tech, Haimen, China) according to the manufacturer's protocol. Thirty μg of the extracted protein samples were separated using 12% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. Primary antibody incubation was carried out overnight at 4°C using mouse monoclonal antibodies against cathepsin B (1: 1000, Abcam, Cambridge, UK) and nuclear factor kappa B (NF-κB) p50 (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Membranes were then probed with the corresponding IgG-HRP. Protein bands were visualized using enhanced chemiluminescence reagents (Milipore, Billerica, MA, USA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control.
fold changes of identified proteins are listed in Tables  1 and 2 . GO analysis on apoptosis related biological process revealed that 3 up-regulated genes (Anxa1, Cryab, Lmna) and 6 down-regulated genes (Hspa5, Phb, Hspb1, Hspd1, Vdac1, Pdia3) were enriched in the process of apoptosis (Figure 2) .
Of the differentially expressed proteins, cathepsin B (with two matched peptides: GENHCGIESEIVAGIPR and SGVYKHEAGDVMGGHAIR, peptide coverage of 11%), which had not been associated with doxorubicininduced cardiac toxicity identified in previous studies, was selected to be further confirmed by Westernblot analysis. As seen in Figure 3 , the expression of cathepsin B in H9c2 cells was increased during doxorubicin treatment and peaked at 48 h, which was in accordance with the proteomic results. Furthermore, expression of possible cathepsin B regulator NF-κB p50 protein in the nucleus increased after doxorubicin induction, which is consistent with the variation of cathepsin B.
In the current study, we quantitatively compared the global proteomic profiling of rat cardiomyocyte H9c2 cells with and without doxorubicin addition at a clinical relevant concentration, which exhibited an apoptosis-inducing effect, but not significant cellular damage in H9c2 cells (6, 8) . Our proteomic analysis revealed a series of proteins varied in cardiomyocytes after doxorubicin treatment for 48 h, in which 10 differentially regulated proteins were enriched in the biological process of apoptosis, which have been
Results and Discussion
As seen in Figure 1 , our data indicates 0.5 µM doxorubicin exerted a considerable apoptosis-inducing effect on H9c2 cardiomyocytes in a time-dependent manner. We then applied an iTRAQ-based proteomic strategy to assess differential expression of H9c2 cells affected by doxorubicin at 48 h on the proteomic level. Proteins giving tryptic peptides with a 113/115 ratio ≥ 2 were classified as up-regulated and a ratio ≤ 0.5 as down-regulated. We confidently identified a total of 212 non-redundant proteins in the iTRAQ analysis. Twenty-two differentially expressed unique proteins were revealed including 15 up-regulated and 7 downregulated proteins. The protein and gene names, database ID, molecular weight, isoelectric point (pI), and proved to be closely associated with doxorubicininduced cardiac toxicity in previous studies. Among these aberrantly regulated proteins, several proteins such as cardiac troponin-T, prohibitin, and HSP60 have already been described to be involved in the generation of doxorubicin-induced cardiomyopathy (6, (9) (10) (11) .
We selected cathepsin B as a novel candidate doxorubicin-associated protein for the further validation and function study for the following reasons. First, this protein in H9c2 cells increased significantly in the proteomic study. Secondly, the role of cathepsin B in the pathogenesis of doxorubicin-induced cardiomyopathy has not been reported. However, the evidence in cancer cells indicates that cathepsin B is a crucial component in doxorubicin-induced apoptosis. For example, Bien et al. (12) found that cathepsin B could mediate doxorubicin-induced cell death by the mechanisms of loss of activating caspase 3, cleavaging PARP and inhibiting cdk1 et al. in tumor cells. Our Western-blot analysis indicated that doxorubicin induced a time-dependent up-regulation of cathepsin B protein increase in H9c2 cells, which is in accordance with those of our proteomic analysis. This finding suggests cathepsin B is a key regulatory component in doxorubicin-induced cardiomyopathy, which might be similar to its modulatory role in doxorubicin-induced tumor cell death. Bien et al. (12) also found that doxorubicin induces cathepsin B expression and activity via NF-κB in tumor cells, and Li et al. (13) found that expression of NF-κB p50 protein in the nucleus and NF-κB binding activity increased significantly in cardiomyopathy induced by adriamycin. In this study, we also demonstrate that doxorubicin induced cathepsin B expression was accompanied by up-regualtion of NF-κB. Recently, Qiao et al. (14) also found a cooccurrence of NF-κB activation and cathepsin B upregulation in delayed anesthetic preconditioning protection against myocardial infarction. Together with the data of the previous studies, our findings suggest that up-regulation of cathepsin B by doxorubicin in cardiomycytes might be associated closely with NF-κB, and the exact mechanisms still deserve further investigation.
Cathepsin B is a prominent lysosomal protease, and plays an important role in the apoptosis process and myocardial damage (15) . Tsuchida et al. (16) demonstrated that cathepsin B was involved in degradation of myofibrillar proteins in myocardial infarction. Ge et al. (17) also found elevated cathepsin B expression might modulate myocardial apoptosis in patients with dilated cardiomyopathy. Therefore, we proposed that cathepsin B could be increased by doxorubicin, and act as a potent apoptosis inducer during the following myocardial toxicity. However, the exact mechanisms of cathepsin B in doxorubicin induced cardiomyopathy remain not fully elucidated, and deserve further investigation.
Considering its role in doxorubicin-induced tumor cell death, it has been proposed that increasing cathepsin B expression could be a novel strategy to modify susceptibility towards doxorubicin (18) . But our results indicated that up-regulated cathepsin B would also aggravate cardiomyopathy. Therefore, when cathepsin B is considered as an attractive target for sensitizing chemotherapy in cancer, its potential cardiac toxicity must be evaluated carefully first.
In conclusion, in this present study, using iTRAQbased proteomic methods, we identify a panel of differentially expression proteins related to doxorubicin treatment in cardiomyocytes, which might provide clues to clarify novel mechanisms underlying doxorubicin-induced cardiomyopathy. Among these proteins, cathepsin B expression was further confirmed by Western-blots, and our results also suggest that increased cathepsin B expression might be associated with the up-regualtion of NF-κB in doxorubicininduced cardiomyopathy. 
